Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) have been given a consensus rating of “Moderate Buy” by the six analysts that are covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $10.00.

Several analysts recently weighed in on the company. StockNews.com downgraded Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 12th. Craig Hallum lowered their price target on shares of Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday.

Ironwood Pharmaceuticals Price Performance

Shares of IRWD opened at $3.71 on Friday. The firm has a market capitalization of $593.70 million, a price-to-earnings ratio of -123.67 and a beta of 0.34. The company has a 50-day moving average of $3.90 and a 200 day moving average of $4.56. Ironwood Pharmaceuticals has a 1-year low of $3.06 and a 1-year high of $15.70.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.07). The firm had revenue of $91.60 million during the quarter, compared to the consensus estimate of $91.22 million. Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The firm’s revenue for the quarter was down 19.4% compared to the same quarter last year. During the same period last year, the company earned $0.12 EPS. On average, equities analysts anticipate that Ironwood Pharmaceuticals will post 0.08 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Ironwood Pharmaceuticals news, CFO Sravan Kumar Emany sold 11,001 shares of Ironwood Pharmaceuticals stock in a transaction on Monday, November 18th. The shares were sold at an average price of $4.08, for a total value of $44,884.08. Following the transaction, the chief financial officer now directly owns 309,572 shares of the company’s stock, valued at approximately $1,263,053.76. The trade was a 3.43 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 12.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Ironwood Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. Pacer Advisors Inc. raised its stake in Ironwood Pharmaceuticals by 4.0% in the fourth quarter. Pacer Advisors Inc. now owns 11,730,771 shares of the biotechnology company’s stock valued at $51,967,000 after buying an additional 450,949 shares during the last quarter. State Street Corp raised its position in shares of Ironwood Pharmaceuticals by 7.3% in the 3rd quarter. State Street Corp now owns 9,919,865 shares of the biotechnology company’s stock valued at $40,870,000 after purchasing an additional 677,024 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Ironwood Pharmaceuticals by 23.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,904,271 shares of the biotechnology company’s stock worth $7,846,000 after purchasing an additional 364,841 shares in the last quarter. Stonepine Capital Management LLC grew its position in Ironwood Pharmaceuticals by 1,982.8% during the 3rd quarter. Stonepine Capital Management LLC now owns 1,000,000 shares of the biotechnology company’s stock worth $4,120,000 after purchasing an additional 951,988 shares during the last quarter. Finally, AQR Capital Management LLC increased its stake in Ironwood Pharmaceuticals by 45.7% during the 2nd quarter. AQR Capital Management LLC now owns 684,578 shares of the biotechnology company’s stock valued at $4,463,000 after purchasing an additional 214,836 shares in the last quarter.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.